Journal of Volgograd State Medical UniversityJournal of Volgograd State Medical University1994-94801994-9499Volgograd State Medical University11935910.19163/1994-9480-2019-1(69)-120-124Research ArticleNEURORECEPTOROLOGICAL EFFECTS OF ANTIMIGRAINE AGENT 9-DIETHYL-2- (4-METHOXYPHENYL)IMIDAZO[1,2-A] BENZIMIDAZOLAgatsarskayaYa. Vyamorok@gmail.comYakovlevD. Sinfo@eco-vector.comMaltsevD. Sinfo@eco-vector.comSemenovaYu. V.info@eco-vector.comSalikhovD. Ainfo@eco-vector.comSultanovaK. T.info@eco-vector.comAnisimovaV. Ainfo@eco-vector.comFSBEI HE «Volgograd State Medical University» of Public Health Ministry of the Russian FederationSBI «Volgograd Medical Scientific Centre»Research Institute of Physical and Organic Chemistry of Southern Federal University1501201916112012418122022Copyright © 2019, Agatsarskaya Y.V., Yakovlev D.S., Maltsev D.S., Semenova Y.V., Salikhov D.A., Sultanova K.T., Anisimova V.A.2019<p>The 5-НТ2А antagonistic, M-cholinergic, histaminergic and GABA-ergic properties of 9-diethylaminoethyl-2-(4-methoxyphenyl) imidazo [1,2-] benzimidazole dihydrochloride - RU-31 compounds with antimigraine properties were studied. Moderate M-anticholinergic and GABA mimetic action and no effect on histaminergic system were shown for RU-31 compound in vivo models in vitro.</p>5-HT2A-antagonistsserotoninM-cholinoreceptorsGABA-receptorsH1-histaminoreceptorsH2-histaminoreceptors5-НТ2А-антагонистысеротонинМ-холинорецепторыГАМК-рецепторыH1-гистаминовые рецепторыH2-гистаминовые рецепторы[Блаттнер Р. Эксперименты на изолированных препаратах гладких мышц / Р. Блаттнер, Х. Классен, Х. Денерт, Х. Дёринг; пер. с англ. - М.: Мир, 1983. - 208 с.][Руководство по проведению доклинических исследований лекарственных средств. Часть первая / А.Н. Миронов, Н.Д. Бунатян и др. - М.: Г риф и К, 2012. -944 с.][Спасов А.А., Анисимова В.А., Яковлев Д.С., Петров В.И., Минкин В.И. Средства, проявляющие свойства антагонистов серотониновых 5-НТ2А-рецепторов: пат. 2465901 РФ: A61P43, A61K31/4188; № 2011104264; заявл. 07.02.11; опубл. 10.11.12, бюл. № 31.][Яковлев Д.С. Конденсированные азолы - новый класс лигандов серотониновых рецепторов: Автореф. дис.. докт. мед. наук. - Волгоград, 2016.][Abi-Saab W.M. 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex // Neuropsychopharmacology. - 1999. - Jan; № 20 (1). - P. 92-6.][Haitao Wang. 5-HT2 receptors mediate functional modulation of GABA receptors and inhibitory synaptic transmissions in human iPS-derived neurons // Scientific Reports. - 2016. - Article number: 20033.][Guide to Pharmacology [Electronic resource]. URL: http://www.guidetopharmacology.org/GRAC/LigandDisplayF orward?tab=biology&ligandId=277.][Marwood J. Influence of alpha 1-adrenoceptor antagonism of ketanserin on the nature of its 5-HT2 receptor antagonism // Clin. Exp. Pharmacol. Physiol. - 1994. -№ 21 (12). - P. 955-961.][Sattigeri B.M. Effect of picrotoxin and cyproheptadine pretreatment on sodium valproate induced wet dog s h a ke behavior in rats // Int. J. Biol. Med. Res. - 2012. -№ 3 (2). - P. 1606-1608.][Spasov A.A. The derivatives of imidazo[1,2-a]benzimidazole as 5-ht2a receptor antagonists // Russian Journal of Bioorganic Chemistry. - 2016. - Vol. 42, № 4. -P. 397-403.][Stanton T. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics // Biochem. Pharmacol. - 1993. - № 45 (11). - P. 2352-2354.][Yakovlev D.S. Effect of 5-ht2a receptor antagonists on blood flow in the carotid vessels upon elevation of serotonin level // Bulletin of Experimental Biology and Medicine. - 2014. - № 3, Vol. 157. - P. 350-352.]